Skip to main content
. 2012 May;56(5):2598–2603. doi: 10.1128/AAC.05477-11

Table 3.

MIC or MEC of antifungal drugs against Aspergillus sp. strainsl

Strain MIC/MEC (μg/ml) of:
Portion of sequence of cyp51C gene containing mutationk
ITC VRC AMB CASj
BMU29791a 2 8 1 0.25 ATGCGTGCTATCTAC (240A)
AflavCb 2 8 1 0.25 ATGCGTGCTATCTAC (240A)
AflavC-3357c 1 0.25 1 0.25 ATGCGTTCTATCTAC (240S)
AflavC-788d 2 8 1 0.25 ATGCGTGCTATCTAC (240A)
NRRL3357e 1 0.25 1 0.25 ATGCGTTCTATCTAC (240S)
AF-Af ≥16 4 0.5 0.03 NA
AF-Bg ≥16 4 0.5 0.03 NA
AF-Ch ≥16 1 0.5 0.03 NA
AF-Ei 0.5 0.5 0.5 0.03 NA
a

VRC-resistant A. flavus strain isolated from the lung tissue of the patient.

b

A. flavus NRRL3357 transformant carrying the cyp51C gene of A. flavus BMU29791.

c

A. flavus BMU29791 transformant carrying the cyp51C gene of A. flavus NRRL3357.

d

A. flavus NRRL3357 transformant carrying the cyp51C gene with T788G missense mutation.

e

VRC-susceptible A. flavus strain obtained from the Fungal Genetics Stock Center.

f

A. flavus transformant with recombinant plasmid pRG3-AMA1-NotI-A.

g

A. flavus transformant with recombinant plasmid pRG3-AMA1-NotI-B.

h

A. flavus transformant with recombinant plasmid pRG3-AMA1-NotI-C.

i

A. flavus transformant with the empty plasmid pRG3-AMA1-NotI.

j

The antifungal activity of CAS was determined by using MEC.

k

Codons (underlined) and corresponding amino acid residues (in parentheses) are shown. NA, not available.

l

MEC, minimal effective concentration; ITC, itraconazole; VRC, voriconazole; AMB, amphotericin B; CAS, caspofungin.